Document Detail

Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
MedLine Citation:
PMID:  19383643     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)-beta is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN-beta on the other 20 members of the MMP family. METHODS: This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN-beta therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR. RESULTS: RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time. CONCLUSIONS: These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN-beta in MS for at least 6 months.
F Bernal; B Elias; H P Hartung; B C Kieseier
Related Documents :
10508223 - Regulation of matrix metalloproteinases (mmps) and their tissue inhibitors in human myo...
10441523 - Expression of collagenase-3 (mmp-13) in human abdominal aortic aneurysms and vascular s...
20122403 - Nuclear import mechanism of the ejc component mago-y14 revealed by structural studies o...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-04-21
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  15     ISSN:  1352-4585     ISO Abbreviation:  Mult. Scler.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-01     Completed Date:  2009-08-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  721-7     Citation Subset:  IM    
Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich-Heine-University, Düsseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Gene Expression Regulation, Enzymologic / drug effects
Immunologic Factors / therapeutic use
Interferon-beta / therapeutic use*
Leukocytes / drug effects,  physiology
Longitudinal Studies
Matrix Metalloproteinase 14 / genetics
Matrix Metalloproteinase 8 / genetics
Matrix Metalloproteinase 9 / genetics
Matrix Metalloproteinases / genetics*
Matrix Metalloproteinases, Secreted / genetics
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / drug therapy*,  metabolism*
RNA, Messenger / metabolism
Reverse Transcriptase Polymerase Chain Reaction
Tissue Inhibitor of Metalloproteinase-1 / genetics*
Tissue Inhibitor of Metalloproteinase-2 / genetics*
Reg. No./Substance:
0/Immunologic Factors; 0/RNA, Messenger; 0/Tissue Inhibitor of Metalloproteinase-1; 127497-59-0/Tissue Inhibitor of Metalloproteinase-2; 77238-31-4/Interferon-beta; EC 3.4.24.-/Matrix Metalloproteinases; EC 3.4.24.-/Matrix Metalloproteinases, Secreted; EC 3.4.24.-/matrix metalloproteinase 19; EC Metalloproteinase 8; EC Metalloproteinase 9; EC Metalloproteinase 14

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Uncommon acquired Gerbode defect (left ventricular to right atrial communication) following a tricus...
Next Document:  Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation...